Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9668119 | 1.00 | SLC18A3 (0.54) | SLC18A3ALDH1A1SMN1; SMN2APPGAA | |
| SCHEMBL9665275 | 0.98 | SLC18A3 (0.56) | SLC18A3ALDH1A1SMN1; SMN2APPGAA | |
| SCHEMBL8245353 | 0.95 | SLC18A3 (0.56) | SLC18A3ALDH1A1SMN1; SMN2APPGAA | |
| SCHEMBL7447435 | 0.91 | SLC18A3 (0.58) | SLC18A3ALDH1A1SMN1; SMN2APPGAA | |
| SCHEMBL13409600 | 0.89 | SLC18A3 (0.55) | SLC18A3ALDH1A1GAAMAPTKLK7 | |
| SCHEMBL4670842 | 0.85 | SLC18A3 (0.53) | SLC18A3ALDH1A1SMN1; SMN2APPGAA | |
| SCHEMBL4670846 | 0.83 | SLC18A3 (0.52) | SLC18A3ALDH1A1SMN1; SMN2APPGAA | |
| SCHEMBL15563729 | 0.83 | SLC18A3 (0.52) | SLC18A3ALDH1A1SMN1; SMN2APPGAA | |
| SCHEMBL18239382 | 0.83 | SLC18A3 (0.52) | SLC18A3ALDH1A1SMN1; SMN2APPGAA | |
| SCHEMBL2427999 | 0.83 | SLC18A3 (0.52) | SLC18A3ALDH1A1SMN1; SMN2APPGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361668-B2 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | UCB, S.A. (BE) | 2008-04-22 | — | — | US | disclosed |
| US-20050020660-A1 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | UCB, S.A. (BE) | 2005-01-27 | — | — | US | disclosed |
| EP-1438309-A1 | QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS | UCB, S.A. (BE) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003033495-A1 | QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS | UCB, S.A. (BE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020660-A1 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | CHRM2, CHRM3, CHRM1 | SLC18A3 93/4885ALDH1A1 727/4885SMN1; SMN2 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.